Company: Fate Therapeutics
Job title: CDO
Bob Valamehr is the Chief Development Officer at Fate Therapeutics, overseeing the company’s early development activities including “off-the-shelf” cell therapy products derived from the company’s induced pluripotent stem cell platform. Previously, Dr. Valamehr was the Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.
Prospects for Multi-targeting Off-the-Shelf CAR-NK Cells 9:40 am
Describing renewable engineered master cell lines for off-the-shelf adoptive NK cell therapy Discussing a unique approach to utilize both chimeric antigen receptor and CD16 Fc receptor to create a multi-antigen targeting approach in cancer immunotherapy Outlining techniques to enhance persistence and expansion capabilities of NK cellsRead more
day: Day One